Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate in Japanese Patients With Relapsed or Refractory PTCL
NCT02013362Phase 2Completed
- Sponsor
- Mundipharma
- Start
- Mar 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pralatrexate in peripheral T-cell lymphoma (PTCL), sponsored by Mundipharma. Primary endpoint: Objective Response Rate at 3 years. Started Mar 2014; status: completed.
02
Drugs
pralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02013362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013362.